Trodelvy (sacituzumab govitecan-hziy) received accelerated approval on April 22, 2020, for the treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) in adults who have received at least two prior therapies for metastatic disease.

Jun 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Pemigatinib on April 17, 2020.

TiumBio Unveils Promising Initial Clinical Data for TU7710, Its Hemophilia Therapy Candidate, at ISTH 2024.

Tucatinib (Tukysa) is an FDA-approved medication for treating HER2-positive breast cancer, specifically in cases where the cancer is metastatic or inoperable.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

The U.S. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.

The U.S. Food and Drug Administration (FDA) granted approval to Sevenfact on April 1, 2020.

The European Commission has approved Roche's OCREVUS for subcutaneous use, making it the first and only twice-yearly injection for relapsing and primary progressive multiple sclerosis.

The U.S. Food and Drug Administration (FDA) approved Ozanimod, marketed under the brand name Zeposia, on March 25, 2020.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.